Pharmaceuticals · IND CMC Support
CMC and GMP Support for an IND
The short answer
Sponsors filing an IND usually need two things at once: CMC content for the application and a quality system capable of overseeing clinical manufacturing. We build both, sized to the phase, without installing commercial-scale bureaucracy on a Phase 1 program.
Why this matters
- A sponsor quality system built too heavy early is abandoned; built too light, it cannot release material.
- CMO oversight is a sponsor responsibility that cannot be delegated by contract.
- Early documentation decisions determine how much rework the NDA or BLA requires.
Applicable regulations and standards
- 21 CFR 312.23(a)(7)
- CMC content required for the IND.
- FDA Guidance — CGMP for Phase 1 Investigational Drugs
- Phase-appropriate control expectations.
- ICH Q7
- GMP for active pharmaceutical ingredients.
What our consultants actually do
- Build a right-sized sponsor quality system: release, deviations, change control, document control
- Author or review CMC sections and supporting development documentation
- Establish quality agreements and CMO oversight practices
- Set phase-appropriate specifications and stability protocols
- Plan the GMP maturity path toward commercial readiness
Across the product lifecycle
01 / DEVELOP
Development data documented for later filings.
02 / SCALE
Clinical supply scale and controls defined.
03 / TRANSFER
Method and process transfer to the CMO.
04 / VALIDATE
Qualification appropriate to phase.
05 / MANUFACTURE
Clinical batch manufacture and sponsor release.
06 / MAINTAIN
IND amendments and system maturation by phase.
Problems we are usually called about
- Quality agreement that assigns responsibilities nobody at the sponsor performs
- No sponsor review of executed batch records
- Specifications carried forward from the CMO template without justification
Typical deliverables
- Sponsor quality system procedures
- CMC content and development documentation review
- Quality agreement and CMO oversight plan
- Phase-by-phase GMP roadmap
Frequently asked
- We are a virtual company. Is that a problem?
- No, but the oversight has to be real. Virtual sponsors need a small number of well-run processes — release, change control, deviation review and CMO oversight — rather than a full copy of a manufacturer's quality system.
References
More for pharmaceuticals
cGMP, validation and manufacturing quality support for drug products.
- Process ValidationProcess validation for a drug product is a three-stage lifecycle: design the process and its control strategy, qualify commercial-scale performance, and then verify that the process stays in control for as long as it is used.
- Cleaning ValidationCleaning validation demonstrates that a documented cleaning procedure consistently reduces residues to scientifically justified limits on shared equipment.
- cGMP ConsultingcGMP consulting for a drug manufacturer means making 21 CFR Parts 210 and 211 operable in your facility — with procedures your staff can follow, records that reconstruct what happened and a quality unit with the authority to act.
- Technology TransferTechnology transfer succeeds or fails on what the receiving site is given: process understanding, not just a batch record.
- Quality SystemsA pharmaceutical quality system is the set of connected processes — documents, changes, deviations, CAPA, training, release, review — that keep product decisions defensible.
- NDA Manufacturing SupportThis is the site-side companion to an NDA filing: making sure the validated process, the control strategy and the records at the manufacturing site match what the application says, and that the people there can explain it during a pre-approval inspection..
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.